During prolonged in vivo mitotic multiplication of a Plasmodium berghei ANKA clone (8417HP), parasites that contained an enlarged version of chromosome 4 were observed. Restriction mapping and hybridization results demonstrated that the extra DNA present in the enlarged chromosome consists of 2.3-kb tandem repeats, known to be normally located in subtelomeric position at several chromosomal ends but absent in the original chromosome. The inserted 2.3-kb units appeared to interrupt one of the original telomeres and to create an internal (approximately 1-kb-long) telomeric sequence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC362954 | PMC |
| http://dx.doi.org/10.1128/mcb.10.12.6759-6764.1990 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
and antimalarial activities of the ethanol extract of stem bark used for the treatment of malaria in the Western Region of Cameroon.
Front Parasitol
April 2024
National Engineering Research Center for Modernization of Traditional Chinese Medicine - Hakka Medical Resources Branch, Gannan Medical University, Ganzhou, China.
Background: Malaria is one of the leading causes of morbidity and/or mortality in tropical Africa. The spread and development of resistance to chemical antimalarial drugs and the relatively high cost of the latter are problems associated with malaria control and are reasons to promote the use of plants to meet healthcare needs to treat malaria. The aim of this study was to evaluate antiplasmodial activities of extracts of (Mah quat), which is traditionally used for the treatment of malaria in the western region of Cameroon.
View Article and Find Full Text PDFExpression and purification of E140 protein antigen fragments of Plasmodium vivax and Plasmodium berghei for serological assays.
FEBS Open Bio
January 2025
Synthetic and Systems Biology Unit, Institute of Biochemistry, HUN-REN Biological Research Centre, Szeged, Hungary.
Malaria, a life-threatening disease caused by Plasmodium parasites, continues to pose a significant global health threat, with nearly 250 million infections and over 600 000 deaths reported annually by the WHO. Fighting malaria is particularly challenging partly due to the complex life cycle of the parasite. However, technological breakthroughs such as the development of the nucleoside-modified mRNA lipid nanoparticle (mRNA-LNP) vaccine platform, along with the discovery of novel conserved Plasmodium antigens such as the E140 protein, present new opportunities in malaria prevention.
View Article and Find Full Text PDFApplication of Artificial Intelligence for quantifying Plasmodium berghei in blood samples from infected mice.
J Vector Borne Dis
October 2024
Department of Biological Sciences, King AbdulAziz University, Jeddah, Makkah, Saudi Arabia.
Background Objectives: In malaria infection, quantifying blood parasitemia is a critical step for evaluating the severity of the disease. This has generally been conducted manually, and thus, its accuracy depends on the expertise of technicians. There is an urgent need for an automated technique to overcome manual errors.
View Article and Find Full Text PDFmosGILT antibodies interfere with Plasmodium sporogony in Anopheles gambiae.
Nat Commun
January 2025
Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA.
Plasmodium, the causative agents of malaria, are obtained by mosquitoes from an infected human. Following Plasmodium acquisition by Anopheles gambiae, mosquito gamma-interferon-inducible lysosomal thiol reductase (mosGILT) plays a critical role in its subsequent sporogony in the mosquito. A critical location for this development is the midgut, a tissue we show expresses mosGILT.
View Article and Find Full Text PDFModified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei.
Int J Parasitol Drugs Drug Resist
December 2024
W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Baltimore, MD, 21210, USA. Electronic address:
Fosmidomycin and clindamycin target the Plasmodium apicoplast. Combination clinical trials have produced mixed results with the primary problem being the recrudescent infection frequency by day 28. Given that antibiotic efficacy against bacterial infections often depends on the constant drug presence over several days, we hypothesized that the antimalarial blood or liver stage efficacy of fosmidomycin and clindamycin could be improved by implementing a more frequent dosing schedule.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!